Adalta Ltd has released a press release.
East to West cell therapy strategy update
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from AdAlta
- AD-214 clinical advisory board
- FY24 RDTI Refund Received $1.77m
- Transaction, investment facility update
- $1.9 million raised from exercise of 1ADOA options
- Cellular immunotherapy manufacturer secured - Cell Therapies
Later from AdAlta
- Investor Presentation
- R&D Tax Incentive advance received
- SYNBV invest up to $2m in East to West subsidiary
- Trading Halt
- Renounceable Rights Issue to Raise up to $1.3 million
Follow AdAlta into a list and get an email when it puts out news.
Follow AdAlta